Introduction The contribution of programmed cell death ligand-1 (PD-L1) immune checkpoint
molecule toward progression of non-small cell lung cancer (NSCLC) has not yet been …

Purpose: NF1 is a tumor suppressor that negatively regulates Ras signaling. NF1 mutations
occur in lung cancer, but their clinical significance is unknown. We evaluated clinical and …

Background: Lung cancer is the leading cause of brain metastases (BM). The identification
of driver oncogenes and matched targeted therapies has improved outcome in non-small …

Background. The frequency with which targeted tumor sequencing results will lead to
implemented change in care is unclear. Prospective assessment of the feasibility and …

The p53 pathway has been extensively studied for its role in carcinogenesis. Disruption of
the pathway occurs in more than half of all cancers, often leading to a worse prognosis for …

Abstract On March 11, 2016, after an expedited 5-month review, the US Food and Drug
Administration expanded the crizotinib metastatic non-small cell lung cancer (mNSCLC) …

New drugs introduced to the market every year represent privileged structures for particular
biological targets. These new chemical entities (NCEs) provide insight into molecular …

Abstract The neuregulin 1 (NRG1) fusion is a recently identified novel driver oncogene in
invasive mucinous adenocarcinoma of the lung (IMA). After identification of a case of …

The development of immune checkpoint inhibitors has altered the landscape of treatment of
advanced cancers. These drugs are well tolerated and have shown clinical activity against a …

Introduction The efficacy of pemetrexed-based chemotherapy in patients with advanced lung
adenocarcinoma with novel ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1) …